SFX by Ex Libris Inc.

Title:	Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development
Source:	Journal of Medicinal Chemistry [0022-2623] Daqing Sun, Zhihong yr:2014

Basic

Full text

Full text available via American Chemical Society Journals

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Ding, K. "Structure-Based Design of Potent Non-Peptide MDM2 Inhibitors." Journal of the American Chemical Society 127.29 (2005): 10130-10131.
description	2.	Gonzalez-Lopez de Turiso, Felix x. "Rational Design and Binding Mode Duality of MDM2-p53 Inhibitors." Journal of medicinal chemistry 56.10 (2013): 4294967295-70.
description	3.	Lucas, Brian S. "An expeditious synthesis of the MDM2-p53 inhibitor AM-8553." Journal of the American Chemical Society 134.30 (2012): 12855-12860.
description	4.	Chène, P. "Inhibiting the p53–MDM2 interaction: an important target for cancer therapy." Nature reviews. Cancer 3.2 (2003): 102-109.
description	5.	Parks, Daniel J. "Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein-protein interaction through structure-based drug design." Bioorganic & medicinal chemistry letters 16.12 (2006): 3310-3314.
description	6.	Ding, K. "Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction." Journal of medicinal chemistry 49.12 (2006): 3432-5.
description	7.	Marugan, Juan e. "Enantiomerically pure 1,4-benzodiazepine-2,5-diones as Hdm2 antagonists." Bioorganic & medicinal chemistry letters 16.12 (2006): 3115-3120.
description	8.	Hardcastle, I. "Isoindolinone Inhibitors of the Murine Double Minute 2 (MDM2)-p53 Protein-Protein Interaction: Structure-Activity Studies Leading to Improved Potency." Journal of medicinal chemistry 54.5 (2011): 1233-1243.
description	9.	Gonzalez, Ana Z. "Selective and Potent Morpholinone Inhibitors of the MDM2–p53 Protein–Protein Interaction." Journal of medicinal chemistry 57.6 (2014): 2472-2488.
description	10.	Leao, M. "Discovery of a new small-molecule inhibitor of p53-MDM2 interaction using a yeast-based approach." Biochemical pharmacology 85.9 (2013): 1234-1245.
description	11.	Vassilev, Lyubomir T. "In vivo activation of the p53 pathway by small-molecule antagonists of MDM2." Science 303.5659 (2004): 844-848.
description	12.	Ito, K. "Pharmacokinetic analysis of benzodiazepine receptor binding of [123I]iomazenil in human brain." Pharmaceutical research 14.8 (1997): 999-1003.
description	13.	Mattei, P. "Asymmetric Synthesis of (S)-3-Amino-4-methoxy-butan-1-ol by Way of Reductive Amination." Organic process research & development 15.2 (2011): 353-359.
description	14.	Lee, Hui S. "Application of Binding Free Energy Calculations to Prediction of Binding Modes and Affinities of MDM2 and MDMX Inhibitors." Journal of chemical information and modeling 52.7 (2012): 1821-1832.
description	15.	Popowicz, G. "Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery." Cell cycle 9.6 (2010): 1104-1111.
description	16.	Gilleron, P. "Synthesis of a novel conformationally restricted Val-Phe dipeptidomimetic." Journal of peptide science 12.2 (2006): 140-146.
description	17.	Foster, Barbara A. "Pharmacological rescue of mutant p53 conformation and function." Science 286.5449 (1999): 2507-2510.
description	18.	Beutler, B. "Microbe sensing, positive feedback loops, and the pathogenesis of inflammatory diseases." Immunological reviews 227.1 (2009): 248-263.
description	19.	Fischer, PM M. "Peptide, peptidomimetic, and small-molecule antagonists of the p53-HDM2 protein-protein interaction." International journal of peptide research and therapeutics 12.1 (2006): 3-19.
description	20.	Haupt, Y. "Mdm2 promotes the rapid degradation of p53." Nature 387.6630 (1997): 296-9.